Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
12/2009
12/22/2009CA2446916C Delivery of opioids through an inhalation route
12/22/2009CA2434813C Imidazole derivatives
12/22/2009CA2426210C Treatment of pcp addiction and pcp addiction-related behavior
12/22/2009CA2418059C Method of treating neurodegenerative disorders of the retina and optic nerve head
12/22/2009CA2416527C Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
12/22/2009CA2415214C Phosphotetrahydropyran compounds
12/22/2009CA2411568C Compositions for the therapy of dementias
12/22/2009CA2406536C Preparation of injectable suspensions having improved injectability
12/22/2009CA2405593C Macrolides
12/22/2009CA2346847C Novel imidazoles with anti-inflammatory activity
12/22/2009CA2339192C Treatment of addiction and addiction-related behavior
12/22/2009CA2326529C 2-(3,5-bis-trifluoromethyl-phenyl)-n-methyl-n-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide
12/22/2009CA2303973C Prolonged release formulation of carbamazepine
12/17/2009WO2009152430A2 Methods of treatment of bipolar disorder
12/17/2009WO2009152369A1 Pharmaceutical formulation of ketorolac for intranasal administration
12/17/2009WO2009152347A2 Crystalline forms of zotepine hydrochloride
12/17/2009WO2009152168A2 Carboxylic acid salts of 2-amino-3-carbethoxyamino-6-(4-fluoro-benzylamino)-pyridine
12/17/2009WO2009152164A2 Smoking cessation kit and method
12/17/2009WO2009152142A1 Sulfonate salts of flupirtine
12/17/2009WO2009152083A1 5h-pyrr0l0 [2,3-b] pyrazine derivatives for kinase modulation, and indications therefor
12/17/2009WO2009152041A2 Controlled release formulations of pramipexole
12/17/2009WO2009151394A1 Sublingual compositions comprising (2s) - (4e) -n-methyl-5- (3- (5-isopropoxypyridin) yl) -4-penten-2-amine
12/17/2009WO2009151393A1 Novel derivatives of 11-piperazin-l-yldibenzo [b,f] [l,4] thiazepine for treating at least one syndrome or condition associated with schizophrenia and other psychotic disorders
12/17/2009WO2009151392A1 Novel derivatives of 11-piperazin-l-yldibenzo [b,f] [1,4] thiazepine for treating at least one syndrome or condition associated with schizophrenia and other psychotic disorders
12/17/2009WO2009151152A1 Oxycarbamoyl compounds and the use thereof
12/17/2009WO2009151098A1 SULFUR-CONTAINING HETEROCYCLIC DERIVATIVE HAVING β-SECRETASE-INHIBITING ACTIVITY
12/17/2009WO2009151072A1 Tablet quickly disintegrating in the oral cavity and method for producing the same
12/17/2009WO2009151057A1 Process for production of antioxidant active substance
12/17/2009WO2009150686A1 Liposomes capable of effectively binding the beta amyloid peptide
12/17/2009WO2009150614A1 Tetrazole compounds as orexin receptor antagonists
12/17/2009WO2009150474A1 Dihydrotetrabenanzine for the treatment of anxiety
12/17/2009WO2009150388A1 Novel derivatives of (bridged piperazinyl)-1-alcanone and use thereof as p75 inhibitors
12/17/2009WO2009150387A1 Derivatives of 2-oxo-alkyl-1-piperazin-2-one, preparation method thereof and therapeutic use of same
12/17/2009WO2009150331A1 Novel azabicyclic derivatives, preparation method for same, and pharmaceutical compositions containing same
12/17/2009WO2009150141A1 Azabicyclooctyl-quinazolone derivatives useful as nicotinic acetylcholine receptor modulators
12/17/2009WO2009150138A1 Novel oxadiazolyl-diazabicyclononane derivatives and their medical use
12/17/2009WO2009150110A1 Pyrrolidine ether derivatives as nk3 receptor antagonists
12/17/2009WO2009150040A2 Opiorphin for use as a psychostimulant agent
12/17/2009WO2009149820A1 Annelated n-heterocyclic sulfonamides with oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals
12/17/2009WO2009149819A1 Annelated pyrrolidin sulfonamides with oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals
12/17/2009WO2009149649A1 Aralkyl alcohol piperidine derivative and the use as medicament for treating depression thereof
12/17/2009WO2009149562A1 Compositions and methods for modulating nicotinic/nmda receptor function
12/17/2009WO2009149560A1 Compositions and methods for modulating d1-d2 dopamine receptor interaction and function
12/17/2009WO2009149487A2 Compounds for treating symptoms associated with parkinson's disease
12/17/2009WO2009149486A2 Compounds for treating diseases
12/17/2009WO2009149485A2 Compounds for treating amyloidoses
12/17/2009WO2009130600A3 Therapeutic use of at least one botulinum neurotoxin in the treatment of pain associated with diabetic neuropathy
12/17/2009WO2009129401A8 Kinase inhibitors
12/17/2009WO2009125140A3 Treatment of migraines without aura in pregnant women by inhalation of dioxygen gas
12/17/2009WO2009120657A3 Human monoclonal antibodies against amyloid beta protein, and their use as therapeutic agents
12/17/2009WO2009114740A9 Use of gabaa receptor antagonists for the treatment of excessive sleepiness and disorders associated with excessive sleepiness
12/17/2009WO2009112758A3 Novel use of zinc n-acetyltaurinate
12/17/2009WO2009106574A3 Combination comprising a cannabinoid receptor binding compound and an opioid
12/17/2009WO2009046834A3 Use of t140 and optionally retrocyclin-1 as therapeutic agents for the treatment of m. tuberculosis infections
12/17/2009WO2009043481A3 Use of adrenomedullin 13-52 and optionally retrocyclin-1 as a therapeutic agent for the treatment of hcmv infections
12/17/2009WO2009043439A3 Use of retrocyclin- 1 as a therapeutic agent for the treatment of hcmv infections
12/17/2009WO2009043437A3 Use of t140 and optionally retrocyclin-1 as therapeutic agents for the treatment of m. tuberculosis infections
12/17/2009WO2009040072A3 Use of angiotensin i as a therapeutic agent in the treatment of eg aids or tuberculosis
12/17/2009WO2009040071A3 Use of cyclo-rgdfv and optionally angiotensin i as therapeutic agents in the treatment of eg aids or tuberculosis
12/17/2009WO2009040029A3 Use of adrenomedullin as a therapeutic agent for the treatment of excessive angiogenesis
12/17/2009WO2009040028A3 Use of casoxin c and optionally adrenomedullin as therapeutic agents for the treatment of excessive angiogenesis
12/17/2009WO2009039968A3 Use of angiotensin iii as a therapeutic agent in the treatment of eg hbv infection
12/17/2009WO2009039966A3 Use of nf-kappab inhibitor sn50 and optionally angiotensin iii as therapeutic agents in the treatment of eg hbv infection
12/17/2009WO2009039957A3 Use of angiotensin ii as a therapeutic agent in the treatment of eg s. pneumoniae infection
12/17/2009WO2009033796A8 Use of a peptide as a therapeutic agent
12/17/2009WO2009033707A3 Use of retrocyclin-1 as a therapeutic agent for the treatment of hcmv infections
12/17/2009WO2009033661A3 Use of rgdspasskp and optionally angiotensin ii as therapeutic agents in the treatment of eg s. pneumoniae infections
12/17/2009WO2009022068A3 Medicament for treating parkinson's disease
12/17/2009WO2009022067A3 Medicament for treating parkinson's disease
12/17/2009WO2008144931A8 Compositions and methods for modulating gated ion channels
12/17/2009US20090312543 Pyrazole compounds useful as protein kinase inhibitors
12/17/2009US20090312436 Rasagiline for parkinson's disease modification
12/17/2009US20090312435 Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity
12/17/2009US20090312416 Treatment of sleep-wake disorders
12/17/2009US20090312413 Composition Comprising Tanshinone Compounds Isolated From The Extract Of Salviae Miltiorrhizae Radix For Treating Or Preventing Cognitive Dysfunction And The Use Thereof
12/17/2009US20090312412 3,4-diamino-3-cyclobutene-1,2-dione derivatives as potassium channel openers
12/17/2009US20090312400 Methods for Therapy of Neurodegenerative Disease of the Brain
12/17/2009US20090312390 Inhibitors of glycogen synthase kinase-3 (gsk-3) for treating glaucoma
12/17/2009US20090312389 Azabicylic compounds, a process for their preparation and pharmaceutical compositions containing them
12/17/2009US20090312386 Novel crystals of substituted phenylalkanoic acid and method of producing the same
12/17/2009US20090312383 Fused Heterocyclic Compounds
12/17/2009US20090312366 Novel p2x7r antagonists and their use
12/17/2009US20090312364 Novel chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
12/17/2009US20090312361 Novel pharmaceutical compositions for treating acquired chronic pain and associated dysphoria
12/17/2009US20090312356 Nicotinic agonists selective for the alpha7 receptor subtype, the process for the preparation thereof and pharmaceutical compositions therefrom
12/17/2009US20090312347 Novel oxadiazole derivatives and their medical use
12/17/2009US20090312342 Quinazolines useful as modulators of ion channels
12/17/2009US20090312341 Cyclic amine bace-1 inhibitors having a heterocyclic substituent
12/17/2009US20090312329 Cyclic hydroxylamine as psychoactive compounds
12/17/2009US20090312323 Compounds for the treatment of spinal muscular atrophy and other uses
12/17/2009US20090312322 Use of Oxindole Derivatives in the Treatment of Dementia Related Diseases, Alzheimer's Disease and Conditions Associated with Glycogen Synthase Kinase-3
12/17/2009US20090312320 Methods of treatment comprising the administration of haloaryl substituted aminopurines or compositions thereof
12/17/2009US20090312319 Certain chemical entities, compositions and methods
12/17/2009US20090312314 Heteroaromatic monoamides as orexinin receptor antagonists
12/17/2009US20090312307 Heterocyclo inhibitors of potassium channel function
12/17/2009US20090312306 Tetrahydro-5h-pyrido[2,3-d]azepines as 5-ht2c ligands
12/17/2009US20090312298 Methods and Compositions Related to GABA Receptor Subunits
12/17/2009US20090312288 Kinase inhibitors
12/17/2009US20090312253 Methods of effecting Wnt signaling through Dkk structural analysis
12/17/2009US20090311351 Composition containing a cereal milling product
1 ... 515 516 517 518 519 520 521 522 523 524 525 526 527 528 529 530 531 532 533 534 535 ... 1833